IL-10, Inflammation and Atherosclerosis in Psoriatic Arthritis Patients
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
It is known that patients with psoriatic disease have increased risk of cardiovascular diseases (CVD) and cardiovascular death but the relationship of those events with influence of traditional risk factors, inflammatory process, anti inflammatory cytokines, and atherosclerosis is not clear.
The objective: to investigate surrogate atherosclerosis markers in patients with psoriatic arthritis (PsA), skin psoriasis (PS) and their connection to inflammation activity and serum IL-10 level.
Materials and methods. The study was conducted in 2 groups of patients: 42 – with PsA, 20 – with skin psoriasis and 20 healthy subjects. Persons with established CVD, other chronic internal diseases, HIV, diabetes where not included; study groups did not take statins or antihypertensive medications. All included patients and healthy subjects consented to take part in the study and underwent complex of clinical (physical examination, joints and skin examination with DAS28, PASI calculation), laboratory (CRP, hematology, IL-10), ultrasound (examination of the carotid arteries with the surrogate aterosclerosis markers determinations – intima-media thickness (IMT), atherosclerotic plaques (AP)) investigations.
Results. PsA patients demonstrated more severe atherosclerotic changes in carotid arteries compared to PS patients and healthy subjects. The severity of the atherosclerotic process was connected with DAS28, CRP level, index PASI. At the same time PsA patients had highest level of IL-10, which might be a sign of upregulation of the anti inflammatory cytokine synthesis in chronic immuno-inflammatory process.
Conclusion. Atherosclerosis development is more prominent in PsA then in skin psoriasis patients and healthy subjects, which is connected to the inflammatory process activity. IL-10 is increased in PsA patients which could be explained as a defense reaction to the chronic inflammatory state.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Badokin V.V. Terapevticheskaya aktivnost’ i bezopasnost’ artrofoona pri psoriaticheskom artrite / V.V. Badokin, Yu.L. Korsakova // Consilium Medicum [E’lektronny’j resurs]. – 2006. – № 8. – Rezhim dostupa: http://conmed.ru/magazines/ consilium_medicum/212569/212305/. – Data dostupa: 27.03.2014.
Cytokine profiles during infliximab monotherapy in psoriatic arthritis / A. Mastroianni [at al.] // British Journal of Dermatology. – 2005. – Vol. 153, № 3. – P. 531–536.
Gottlieb A.B. Psoriasis comorbidities / A.B. Gottlieb, C. Chao, F. Dann // Journal of Dermatological Treatment. – 2008. – Vol. 19, № 1. – R. 5–21.
Milosavljevic J. Ultrasound and Power Doppler Evaluation of the Hand and Wrist in Patients with Psoriatic Arthritis / J. Milosavljevic, U. Lindqvist, A. Elvin // Acta Radiologica. – 2005. – Vol. 46, № 4. – P. 374–385.
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics / A. Gottlieb [at al.] // Journal of the American Academy of Dermatology. – 2008. – Vol. 58, № 5. – P. 851– 864.
Effects of alefacept on health-related quality of life in patients with psoriasis results from a randomized, placebo-controlled phase II trial / C.N. Ellis [at al.] // American Journal of Clinical Dermatology. – 2003. – Vol. 4, № 2. – P. 131–139.
Stefano I. Echographic test and cyclosporin therapy in psoriatic arthritis / I. Stefano, R. Eugenio, R. Antonio // Journal of the European Academy of Dermatology and Venereology. – 2000. – Vol. 14, № 3. – P. 232–233.
Kochergin N.G. Itogi raboty’ Pervoj vsemirnoj konferencii po psoriazu i psoriaticheskomu artritu / N.G. Kochergin, S.N. Kochergin, L.M. Smirnova // Russkij medicinskij zhurnal [E’lektronny’j resurs]. – 2006. – Rezhim dostupa: http://www.rmj.ru/articles_4306.htm. – Data dostupa: 03.04.2014.
Psoriasis and diabetes: a populationbased cross-sectional study / A.D. Cohen [at al.] // Journal of the European Academy of Dermatology and Venereology. – 2008. – Vol. 22, № 5. – R. 585–589.
Kovalenko V.M. Vpliv іmunnogo statusu і lіpіdnikh faktorіv na progresuvannya subklіnіchnogo aterosklerozu і rozvitok sertsevo-sudinnikh zakhvoryuvan u patsіentіv іz revmatoїdnim artritom // Kovalenko V.M., L.V. Khimion, G.І. Lysenko, O.O. Garmisch / Ukr. tevmatol. Zhurn. – 2011.
Gonzalez-Juanatey C., Llorca J., Amigo-Diaz E. [et al.] High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. // Arthritis Rheum. – 2007. – 57 (6). – Р. 1074–1080.
Lakoski S.G. Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study /Susan G. Lakoski, Yongmei Liu K et al. // Atherosclerosis. – 2008. – Vol. 197 (1), March. – P. 443–447.
Caligiuri G. Interleukin-10 Deficiency Increases Atherosclerosis, Thrombosis, and Low-density Lipoproteins in Apolipoprotein E Knockout Mice / Giuseppina Caligiuri, Mats Rudling, Véronique Ollivier et al. // Molecular Medicine. – 2003. – Vol. 9. – P. 10–17.
Heeschen Ch. Serum Level of the Antiinflammatory Cytokine Interleukin-10 Is an Important Prognostic Determinant in Patients With Acute Coronary Syndromes / Christopher Heeschen, Stefanie Dimmeler, Christian W. Hamm, et al.// 2003. – Vol. 107. – P. 2109–2114.
Malarstig A. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome / A. Malarstig, P. Eriksson, A. Hamsten et al. // Heart. – 2008. – Vol. 94. – P. 724–729.
